5.460SEK-0.73%Mkt Cap: 176.84M SEKP/E: —Last update: 2026-05-13
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also …
Industry Peers
Diagnostics & Researchloading…
Indicators:|
Key Statistics
Valuation
P/E (Trailing)—
P/E (Forward)-54.40
PEG—
P/B1.93
P/S2.98
EV/EBITDA-35.92
EV/Revenue2.64
EPS (TTM)-0.39
EPS (Forward)-0.10
Cash Flow & Leverage
FCF Yield-6.52%
FCF Margin-19.47%
Operating CF-6.82M SEK
CapEx (TTM)5.49M SEK
Net Debt/EBITDA4.65
Net Debt-20.28M SEK
Technical
SMA 505.246 (+4.1%)
SMA 2005.783 (-5.6%)
Beta0.54
S&P 52W Chg24.23%
Avg Vol (30d)19.52K
Avg Vol (10d)14.80K
Technical Indicators
RSI (14)51.9
MACD0.0683
MACD Signal0.0605
MACD Hist.+0.0078
BB Upper5.747 SEK
BB Middle5.457 SEK
BB Lower5.167 SEK
BB Width10.62%
ATR (14)0.2801 SEK
Vol Ratio (20d)0.18x
52W Range
4.49041% of range6.840
52W High6.840 SEK
52W Low4.490 SEK
Profitability
Gross Margin64.80%
EBITDA Margin-7.35%
Profit Margin-19.99%
Oper. Margin-14.20%
ROE-14.91%
ROA-9.98%
Revenue Growth9.50%
Earnings Growth—
Balance Sheet
Debt/Equity0.24
Current Ratio2.95
Quick Ratio2.64
Book Value/Sh2.821 SEK
Cash/Share1.171 SEK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 SEK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Ownership
Shares Out.32.51M
Float24.40M
Insiders24.90%
Institutions12.11%
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Company
Market Cap176.84M SEK
Enterprise Value156.57M SEK
Revenue (TTM)59.27M SEK
Gross Profit37.57M SEK
Net Income (TTM)-11.59M SEK
Revenue/Share1.959 SEK
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees36
Last Price5.460 SEK
CountrySE
SectorHealthcare
IndustryDiagnostics & Research
ISIN—